|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 660 PENNSYLVANIA AVE, SE |
Address2 | SUITE 201 |
| City | WASHINGTON |
State | DC |
Zip Code | 20003 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 1171-87
|
||||||||
|
6. House ID# 317490005
|
||||||||
| TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Alicia Fitzpatrick, Executive Assistant |
Date | 04/14/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
legislation affecting the production of medical isotopes
legislation to upgrade security of radiopharmaceutical facilities
HR 3276, American Medical Isotopes Production Act of 2009
HR 515, Prohibit the importation of certain low-level radioactive waste
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Massie |
|
|
|
Richard |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of Prescription Drug User Fee Act of 2007, provision affecting PET drugs and medical advisory committees.
Buyer/Matheson's E-pedigree and radiopharmaceuticals legislation draft, provisions affecting radiopharmaceuticals and PET drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA),
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Courtney |
Johnson |
|
|
|
James |
Massie |
|
|
|
Richard |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Food and Drug Import Safety Act, provision affecting medical isotope import requirements
Senate Drug and Safety Accountability
House Energy and Commerce Drug Administration discussion draft
S. 510, FDA Food Safety Modernization Act
S. 882, Drug and Device Accountability Act of 2009
HR 759, Food and Drug Administration Globalization Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Massie |
|
|
|
Courtney |
Johnson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
HR 3590, Patient Protection and Affordable Care Act of 2010, provisions dealing with Medicare payment for radiopharmaceuticals
HR 4872, Healthcare and Education Reconciliation Act of 2010, provisions dealing with Medicare payment for radiopharmaceuticals
HR 3200, America's Affordable Health Choices Act of 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Courtney |
Johnson |
|
|
|
James |
Massie |
|
|
|
Richard |
White |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
23 |
|
||||||
| 2 |
|
24 |
|
||||||
| 3 |
|
25 |
|
||||||
| 4 |
|
26 |
|
||||||
| 5 |
|
27 |
|
||||||
| 6 |
|
28 |
|
||||||
| 7 |
|
29 |
|
||||||
| 8 |
|
30 |
|
||||||
| 9 |
|
31 |
|
||||||
| 10 |
|
32 |
|
||||||
| 11 |
|
33 |
|
||||||
| 12 |
|
34 |
|
||||||
| 13 |
|
35 |
|
||||||
| 14 |
|
36 |
|
||||||
| 15 |
|
37 |
|
||||||
| 16 |
|
38 |
|
||||||
| 17 |
|
39 |
|
||||||
| 18 |
|
40 |
|
||||||
| 19 |
|
41 |
|
||||||
| 20 |
|
42 |
|
||||||
| 21 |
|
43 |
|
||||||
| 22 |
|
44 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
| RIT Oncology |
|
|
||||||||||||
| Covidien |
|
|
||||||||||||
| DRAXIMAGE |
|
|
||||||||||||
| Eckert & Ziegler Istopes Inc |
|
|
||||||||||||
| GE Healthcare |
|
|
||||||||||||
| GlaxoSmithKline |
|
|
||||||||||||
| International Isotopes |
|
|
||||||||||||
| Lantheus Medical Imaging |
|
|
||||||||||||
| MDS Nordion |
|
|
||||||||||||
| Cardinal Health, Nuc Pharm Services |
|
|
||||||||||||
| PerkinElmer Life and Analytical Sci. |
|
|
||||||||||||
| PETNET Solutions, Inc |
|
|
||||||||||||
| QSA Global, Inc |
|
|
||||||||||||
| Cellectar |
|
|
||||||||||||
| EUSA Pharma |
|
|
||||||||||||
| Alseres Pharmaceutical Molecular Im |
|
|
||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 12 | 23 |
| 2 | 13 | 24 |
| 3 | 14 | 25 |
| 4 | 15 | 26 |
| 5 | 16 | 27 |
| 6 | 17 | 28 |
| 7 | 18 | 29 |
| 8 | 19 | 30 |
| 9 | 20 | 31 |
| 10 | 21 | 32 |
| 11 | 22 | 33 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 23 | 45 |
| 2 | 24 | 46 |
| 3 | 25 | 47 |
| 4 | 26 | 48 |
| 5 | 27 | 49 |
| 6 | 28 | 50 |
| 7 | 29 | 51 |
| 8 | 30 | 52 |
| 9 | 31 | 53 |
| 10 | 32 | 54 |
| 11 | 33 | 55 |
| 12 | 34 | 56 |
| 13 | 35 | 57 |
| 14 | 36 | 58 |
| 15 | 37 | 59 |
| 16 | 38 | 60 |
| 17 | 39 | 61 |
| 18 | 40 | 62 |
| 19 | 41 | 63 |
| 20 | 42 | 64 |
| 21 | 43 | 65 |
| 22 | 44 | 66 |